Clinical study of immunotherapy for unresectable advanced pancreatic cancer.

Clinical study of immunotherapy for unresectable advanced pancreatic cancer. - Clinical study of immunotherapy for unresectable advanced pancreatic cancer.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001135

Enrollment

Registered

2008-04-25

Start date

2008-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Intratumoral dendritic cells injection Chemotherapy: Gemcitabine(1000mg/m2)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histologically or cytologically proven unresectable advanced pancreatic cancer. At least one measurable lesion. Age: 20-75 years old. Performance status 0-2. No serious abnormality in bone marrow, liver and/or renal functions.

Exclusion criteria

Exclusion criteria: patients who have: uncontrolled infections; active autoimmune diseases; serious cardiac disease, and who have received continuous systemic steroids.

Design outcomes

Primary

Measure	Time frame
Clinical responses/Safety	—

Secondary

Measure	Time frame
immune response	—

Countries

Japan

Contacts

Public ContactItoi Takao

Tokyo Medical University Hospital Department of Hepatology and Gastroenterology

itoi@tokyo-med.ac.jp03-3342-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026